EXPLORE!

FDA Approves Yutrepia (treprostinil) Inhalation Powder for Pulmonary Hypertension

  432 Views

Emedinexus    29 May 2025

The U.S. FDA has approved Yutrepiainhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Yutrepia is a dry powder formulation of the prostacyclin analog treprostinil, offering a targeted inhaled therapy to improve exercise capacity in affected patients.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.